The pharmacotherapy management of patients with heart failure with reduced ejection fraction is a populated landscape with multiple drugs affecting morbidity and mortality. Two new medications that are the first in two new classes were approved recently - a neprilysin inhibitor and a hyperpolarization-activated cyclic nucleotide-gated channel blocker.
But first here's a quick table and a few notes about the current use of medications for treating heart failure with reduced ejection fraction.
HughesMedicine - Pharmacotherapy Pearls from the Internal Medicine Clinical Pharmacist
Recommended for you
-
Bleeding risk with anticoagulant and antiplatelet medications is something that we struggle with on a regular basis. Should we fully anti...
-
Let’s start with a patient case. An elderly patient has recently arrived from Italy and you are performing the medication reconciliation f...
-
Since it's the time of year again when Lyme disease is a concern for patients in many parts of the United States, I thought it would b...
-
The American Geriatrics Society recently published their Alternative Treatments to Selected Medications in reference to the most recent upd...
-
Hepatic encephalopathy is a frequent and debilitating complication of liver disease. The mainstay of treatment, lactulose, has been used ...
-
Let’s start with a patient case. A patient is being treated with methylprednisolone 20 mg IV q6 hours for some inflammatory process and...
-
Let’s start with a patient scenario. A patient presents to the emergency room experiencing a heart failure exacerbation. When entering th...
-
Thiamine is a water-soluble vitamin that is an important coenzyme for various metabolic processes in the body. These include the regulat...
-
Ticagrelor is an antiplatelet medication that is commonly used for a number of cardiovascular conditions. Its mechanism is similar to th...
-
Let's start with a patient case. A 70 year old male patient is admitted to the hospital for a diabetic foot infection. He has a past...
